Platelet activating factor acetylhydrolase is associated with cardiac valvular calcification in dialysis patients
Open Access
- 30 January 2024
- journal article
- research article
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 274-282
Abstract
Objectives: The cardiovascular mortality risk is greatly increased in patients with chronic kidney disease (CKD), especially in dialysis patients, due to atherosclerosis. Platelet activating factor acetylhydrolase (PAF-AH) is an enzyme that hydrolyzes platelet activating factor (PAF). Valvular calcifications and PAF-AH are associated with atherosclerosis. However, little is known about the status of PAF-AH activity and valvular calcification in dialysis patients. Therefore, the aim of this study was to investigate the status of these parameters in CKD patients. Methods: This study included 92 chronic renal failure (CRF) (dialysis group), and 86 CKD patients (non-dialysis group). Echocardiography was performed to assess valvular calcification. Results: There was no significant difference between the dialysis and CKD groups in terms of PAF-AH activities. However, when comparisons were stratified according to the presence of valve calcification, higher PAF-AH activity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were evident in patients with calcification compared to those without. Additionally, the CRF group also exhibited elevated PAF-AH and NT-proBNP levels. While elevated NT-proBNP persisted in the CKD group, in contrast, changes in PAF-AH were not significant. Conclusions: The results of this study suggest that high PAF-AH and NT-proBNP levels are associated with valvular calcification in dialysis patients. Both biomarkers may be used as a risk factor for calcification. Furthermore, inhibition of PAF-AH activity may be a treatment target to reduce calcification.Keywords
This publication has 35 references indexed in Scilit:
- Impact of Plasma Lp-PLA2 Activity on the Progression of Aortic StenosisJACC: Cardiovascular Imaging, 2015
- B-Type Natriuretic Peptide Clinical Activation in Aortic StenosisJACC, 2014
- Elevated Expression of Lipoprotein-Associated Phospholipase A2 in Calcific Aortic Valve DiseaseJACC, 2014
- The platelet activating factor (PAF) signaling cascade in systemic inflammatory responsesBiochimie, 2010
- Impaired antioxidant activity of high-density lipoprotein in chronic kidney diseaseTranslational Research, 2009
- Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolaseAtherosclerosis Supplements, 2002
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureNew England Journal of Medicine, 2002
- Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis proceduresKidney International, 1999
- Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.Journal of Biological Chemistry, 1987
- Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF)Clinical Immunology and Immunopathology, 1980